http://www.cnr.it/ontology/cnr/individuo/prodotto/ID13586
Washout of 99mTc-Sestamibi in predicting response to chemoterapy in patients with multiple myeloma (Articolo in rivista)
- Type
- Label
- Washout of 99mTc-Sestamibi in predicting response to chemoterapy in patients with multiple myeloma (Articolo in rivista) (literal)
- Anno
- 2005-01-01T00:00:00+01:00 (literal)
- Alternative label
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
- Pace L; Catalano L; Del Vecchio S; De Renzo A; Fonti R; Salvatore B; Andretta C; Di Nuzzo C; Rotoli B; Salvatore M. (literal)
- Pagina inizio
- Pagina fine
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
- Rivista
- Note
- ISI Web of Science (WOS) (literal)
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
- Nuclear Medicine Unit, Department of Biomorphological and Functional Sciences, \"Federico II\" University, Naples, Italy;
Institute of Biostructures and Bioimaging,CNR, Naples, Italy;
Hematology Division,Department of Clinical and Experimental Medicine,\"Federico II\" University, Naples, Italy (literal)
- Titolo
- Washout of 99mTc-Sestamibi in predicting response to chemoterapy in patients with multiple myeloma (literal)
- Abstract
- Aim. Technetium-99m 2-methoxy-isobutyl-isonitrile
([99mTc] MIBI) has been successfully used to study patients
with multiple myeloma (MM). This tracer is also a substrate
for P-glycoprotein (Pgp). Since Pgp overexpression
is one of the primary mechanisms of multidrug resistance
in MM, the aim of this study was to test whether
[99mTc] MIBI could be an index of Pgp overexpression
and function in MM and therefore predicts response to
chemotherapy.
Methods. Forty patients with MM (12 in stage I, 15 in
stage II, and 13 in stage III) showing diffuse bone marrow
[99mTc] MIBI uptake were included in the study. All
patients underwent whole body scintigraphy at 10 and
60 minutes after i.v. injection of 555 MBq of [99mTc] MIBI.
[99mTc] MIBI washout was measured, after decay correction,
as: (10 minute counts/pixel minus 60 minute
counts/pixel) divided by 10 minute counts/pixel, computed
on a region of interest drawn on the thoracic
spine (posterior projection), taking care of avoiding
heart and splancnic organs. Disease restaging was performed
at a mean time of 32±20 months, and patients
were considered to be in remission (complete or partial)
or to show disease progression on the basis of a complete
clinical and hematological evaluation.
Results. Patients showing disease progression at restaging
(n=26) had higher washout (19.3±9.8 % vs 12.8±6.9%,
p<0.05) than patients in remission (n=14). Disease free
survival was significantly better in patients with lower
washout of [99mTc] MIBI. No differences in therapeutic
regimen and stage of disease at admission were found
between the 2 groups. When patients treated with melphalan were excluded from the analysis, 87.5% of
patients in remission had low washout.
Conclusion. The present study suggests a potential role
of [99mTc] MIBI washout in predicting response to
chemotherapy in patients with MM. (literal)
- Prodotto di
- Autore CNR
Incoming links:
- Autore CNR di
- Prodotto
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi